|Articles|March 30, 2023
Setting Sustainability Goals with Pierre Luzeau (DCAT 2023)
Author(s)Grant Playter
Pierre Luzeau, CEO of Seqens, discusses Seqen's commitment to sustainability and how one can work toward it within their own company.
Advertisement
As part of ongoing coverage of DCAT, the PharmTech editors touched base with Pierre Luzeau, CEO of Seqens. In in our discussion, Pierre discussed various aspects of sustainability, including:
- The extensive measures his company has put in place to committ to sustainability
- Underappreciated practices and techniques that contribute to sustainability
- Why sustainability will be so pivotal for biopharma companies over the course of the next ten years.
For more of our coverage on DCAT in 2023, viewers can visit
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
5
